CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Acquired by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. increased its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 9.2% during the 4th quarter, Holdings Channel.com reports. The fund owned 44,305 shares of the company’s stock after purchasing an additional 3,737 shares during the quarter. Hennion & Walsh Asset Management Inc.’s holdings in CRISPR Therapeutics were worth $1,744,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Baker BROS. Advisors LP increased its position in shares of CRISPR Therapeutics by 743.1% during the third quarter. Baker BROS. Advisors LP now owns 843,075 shares of the company’s stock worth $39,608,000 after purchasing an additional 743,075 shares in the last quarter. State Street Corp grew its stake in CRISPR Therapeutics by 25.0% during the 3rd quarter. State Street Corp now owns 2,992,988 shares of the company’s stock worth $140,611,000 after buying an additional 599,304 shares during the last quarter. Farallon Capital Management LLC acquired a new position in CRISPR Therapeutics during the second quarter worth approximately $28,625,000. Marshall Wace LLP purchased a new stake in CRISPR Therapeutics in the second quarter valued at approximately $10,078,000. Finally, Granite Bay Wealth Management LLC acquired a new stake in shares of CRISPR Therapeutics in the second quarter valued at approximately $2,375,000. 69.20% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. Royal Bank of Canada reiterated a “sector perform” rating and issued a $53.00 price target on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. Bank of America decreased their target price on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. StockNews.com upgraded CRISPR Therapeutics to a “sell” rating in a research report on Monday, December 30th. Needham & Company LLC reaffirmed a “buy” rating and set a $84.00 price objective on shares of CRISPR Therapeutics in a research report on Tuesday. Finally, Chardan Capital reissued a “buy” rating and issued a $94.00 target price on shares of CRISPR Therapeutics in a report on Tuesday, December 10th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $78.38.

CRISPR Therapeutics Trading Up 0.6 %

Shares of CRISPR Therapeutics stock opened at $40.53 on Friday. The company has a 50-day moving average of $45.01 and a two-hundred day moving average of $48.16. CRISPR Therapeutics AG has a 12-month low of $36.52 and a 12-month high of $91.10. The stock has a market cap of $3.46 billion, a PE ratio of -14.32 and a beta of 1.68.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its earnings results on Tuesday, November 5th. The company reported ($1.01) EPS for the quarter, topping analysts’ consensus estimates of ($1.42) by $0.41. The company had revenue of $0.60 million for the quarter, compared to the consensus estimate of $6.65 million. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. During the same period in the previous year, the business earned ($1.41) earnings per share. On average, sell-side analysts forecast that CRISPR Therapeutics AG will post -5.13 EPS for the current fiscal year.

Insider Buying and Selling at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 30,000 shares of the company’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $55.62, for a total value of $1,668,600.00. Following the sale, the chief executive officer now directly owns 196,540 shares in the company, valued at $10,931,554.80. This represents a 13.24 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 4.10% of the stock is owned by insiders.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.